Literature DB >> 23390571

Evaluation of coronary microvascular function in patients with vasospastic angina.

Hiroki Teragawa1, Naoya Mitsuba, Ken Ishibashi, Kenji Nishioka, Satoshi Kurisu, Yasuki Kihara.   

Abstract

AIM: To investigate endothelium-dependent and -independent coronary microvascular functions in patients with vasospastic angina (VSA).
METHODS: Thirty-six patients with VSA (30 men and 6 women; mean age, 58 years) were enrolled in this study. VSA was defined as ≥ 90% narrowing of the epicardial coronary arteries on angiography performed during a spasm provocation test, presence of chest pain, and/or ST-segment deviation on an electrocardiogram (ECG). Patients (n = 36) with negative spasm provocation test results and those matched for age and sex were enrolled as a control group (nonVSA group). Low-dose acetylcholine (ACh; 3 μg/min) was infused into the left coronary ostium for 2 min during the spasm provocation test. Following the spasm provocation test, nitroglycerin (0.2 mg) was administered intracoronally. Coronary blood flow (was calculated from quantitative angiography and Doppler flow velocity measurements, and the coronary flow reserve was calculated as the ratio of coronary flow velocity after injection of adenosine triphosphate (20 μg) to the baseline value. Changes in the coronary artery diameter in response to ACh and nitroglycerin infusion were expressed as percentage changes from baseline measurements.
RESULTS: Body mass index was significantly lower in the VSA group than in the nonVSA group. The frequency of conventional coronary risk factors and the rate of statin use were similar between the 2 groups. The left ventricular ejection fraction as evaluated by echocardiography was similar between the 2 groups. The duration of angina was 9 ± 2 mo. The results of blood chemistry analysis were similar between the 2 groups. Low-dose ACh did not cause coronary spasms. The change in coronary artery diameter in response to ACh was lower in the VSA group (-1.4% ± 9.3%) than in the nonVSA group (3.1% ± 6.5%, P < 0.05), whereas nitroglycerin-induced coronary artery dilatation and coronary blood flow increase in response to ACh or coronary flow reserve did not differ significantly between the 2 groups.
CONCLUSION: These findings suggest that microvascular coronary function may be preserved despite endothelial dysfunction of the epicardial coronary arteries in patients with VSA.

Entities:  

Keywords:  Acetylcholine; Coronary spasm; Endothelial function

Year:  2013        PMID: 23390571      PMCID: PMC3565162          DOI: 10.4330/wjc.v5.i1.1

Source DB:  PubMed          Journal:  World J Cardiol


  33 in total

1.  Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm.

Authors:  H Shimokawa; M Seto; N Katsumata; M Amano; T Kozai; T Yamawaki; K Kuwata; T Kandabashi; K Egashira; I Ikegaki; T Asano; K Kaibuchi; A Takeshita
Journal:  Cardiovasc Res       Date:  1999-09       Impact factor: 10.787

2.  Tetrahydrobiopterin improves coronary endothelial function, but does not prevent coronary spasm in patients with vasospastic angina.

Authors:  Yukihiro Fukuda; Hiroki Teragawa; Keiji Matsuda; Togo Yamagata; Hideo Matsuura; Kazuaki Chayama
Journal:  Circ J       Date:  2002-01       Impact factor: 2.993

3.  Magnesium causes nitric oxide independent coronary artery vasodilation in humans.

Authors:  H Teragawa; M Kato; T Yamagata; H Matsuura; G Kajiyama
Journal:  Heart       Date:  2001-08       Impact factor: 5.994

4.  [Evaluation of coronary flow reserve in patients with vasospastic angina].

Authors:  H Anzai; T Saijo; R Nakajima; N Tezuka; T Takagi; T Tsunoda; N Kobayashi; S Nakamura; T Yamaguchi
Journal:  J Cardiol       Date:  2000-07       Impact factor: 3.159

Review 5.  Overview of gender aspects of cardiac syndrome X.

Authors:  Juan Carlos Kaski
Journal:  Cardiovasc Res       Date:  2002-02-15       Impact factor: 10.787

6.  Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina.

Authors:  Akihiro Masumoto; Masahiro Mohri; Hiroaki Shimokawa; Lemmy Urakami; Makoto Usui; Akira Takeshita
Journal:  Circulation       Date:  2002-04-02       Impact factor: 29.690

7.  Myocardial bridging increases the risk of coronary spasm.

Authors:  Hiroki Teragawa; Yukihiro Fukuda; Keiji Matsuda; Hidekazu Hirao; Yukihito Higashi; Togo Yamagata; Tetsuya Oshima; Hideo Matsuura; Kazuaki Chayama
Journal:  Clin Cardiol       Date:  2003-08       Impact factor: 2.882

8.  Response of the left anterior descending coronary artery to acetylcholine in patients with chest pain and angiographically normal coronary arteries.

Authors:  Keiji Matsuda; Hiroki Teragawa; Yukihiro Fukuda; Kentaro Ueda; Yukihito Higashi; Kenya Sakai; Fumiharu Miura; Hidekazu Hirao; Togo Yamagata; Masao Yoshizumi; Kazuaki Chayama
Journal:  Am J Cardiol       Date:  2003-12-15       Impact factor: 2.778

9.  Coronary flow reserve in patients with vasospastic angina: correlation between coronary flow reserve and age or duration of angina.

Authors:  Shozo Sueda; Hiroaki Kohno; Hiroshi Fukuda; Tadao Uraoka
Journal:  Coron Artery Dis       Date:  2003-09       Impact factor: 1.439

10.  Induction of coronary artery spasm by two pharmacological agents: comparison between intracoronary injection of acetylcholine and ergonovine.

Authors:  Shozo Sueda; Hiroaki Kohno; Hiroshi Fukuda; Naoto Ochi; Hiroyuki Kawada; Yutaka Hayashi; Tadao Uraoka
Journal:  Coron Artery Dis       Date:  2003-09       Impact factor: 1.439

View more
  3 in total

Review 1.  Diagnosis of coronary microvascular dysfunction - Present status.

Authors:  S R Mittal
Journal:  Indian Heart J       Date:  2015-11-06

2.  Positive influence of aspirin on coronary endothelial function: Importance of the dose.

Authors:  Hiroki Teragawa; Naoya Mitsuba; Ken Ishibashi; Satoshi Kurisu; Yasuki Kihara
Journal:  World J Cardiol       Date:  2013-11-26

3.  Coronary spasm: It's common, but it's still unsolved.

Authors:  Hiroki Teragawa; Chikage Oshita; Tomohiro Ueda
Journal:  World J Cardiol       Date:  2018-11-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.